OBJECTIVE: To evaluate the frequency and duration of episodes of definitive vertigo in Ménière's disease. DESIGN: Prospective longitudinal study. SETTING: Multiple tertiary referral centers. PATIENTS: Five hundred ten individuals from 8 hospitals that met the American Academy of Otolaryngology-Head and Neck Surgery diagnostic criteria for definitive Ménière's disease. INTERVENTION: Conservative treatment. MAIN OUTCOME MEASURE: Frequency and duration of episodes of definitive vertigo during follow-up. RESULTS: Ménière's disease affects both sexes and both ears equally, with onset generally in the fourth decade of life. The number of episodes of vertigo is greater in the first few years of the disease. Although episodes of vertigo that last longer than 6 hours are less frequent than shorter episodes, they occur with similar frequency throughout the natural course of the disease. The percentage of patients without episodes of vertigo increases as the disease progresses, and 70% of patients who did not have an episode of vertigo for 1 year will continue to be free of episodes during the following year. Thus, there is a relationship between the frequency of episodes in consecutive years, although this association decreases rapidly as the number of years increases. CONCLUSION: The frequency of definitive episodes of vertigo in Ménière's disease decreased during follow-up, and many individuals reached a steady-state phase free of vertigo.
OBJECTIVE: To evaluate the frequency and duration of episodes of definitive vertigo in Ménière's disease. DESIGN: Prospective longitudinal study. SETTING: Multiple tertiary referral centers. PATIENTS: Five hundred ten individuals from 8 hospitals that met the American Academy of Otolaryngology-Head and Neck Surgery diagnostic criteria for definitive Ménière's disease. INTERVENTION: Conservative treatment. MAIN OUTCOME MEASURE: Frequency and duration of episodes of definitive vertigo during follow-up. RESULTS: Ménière's disease affects both sexes and both ears equally, with onset generally in the fourth decade of life. The number of episodes of vertigo is greater in the first few years of the disease. Although episodes of vertigo that last longer than 6 hours are less frequent than shorter episodes, they occur with similar frequency throughout the natural course of the disease. The percentage of patients without episodes of vertigo increases as the disease progresses, and 70% of patients who did not have an episode of vertigo for 1 year will continue to be free of episodes during the following year. Thus, there is a relationship between the frequency of episodes in consecutive years, although this association decreases rapidly as the number of years increases. CONCLUSION: The frequency of definitive episodes of vertigo in Ménière's disease decreased during follow-up, and many individuals reached a steady-state phase free of vertigo.
Authors: J A Lopez-Escamez; J Carey; W-H Chung; J A Goebel; M Magnusson; M Mandalà; D E Newman-Toker; M Strupp; M Suzuki; F Trabalzini; A Bisdorff Journal: HNO Date: 2017-11 Impact factor: 1.284
Authors: C Martín González; F M González; A Trinidad; A Ibáñez; M Pinilla; A Martínez Ruiz-Coello; A Rodríguez Valiente; C López-Cortijo Journal: Eur Arch Otorhinolaryngol Date: 2010-05-08 Impact factor: 2.503
Authors: Irene Gazquez; Andres Soto-Varela; Ismael Aran; Sofia Santos; Angel Batuecas; Gabriel Trinidad; Herminio Perez-Garrigues; Carlos Gonzalez-Oller; Lourdes Acosta; Jose A Lopez-Escamez Journal: PLoS One Date: 2011-10-28 Impact factor: 3.240
Authors: B F van Esch; K Abolhosseini; S Masius-Olthof; H J van der Zaag-Loonen; P P G van Benthem; Tj D Bruintjes Journal: J Vestib Res Date: 2018 Impact factor: 2.354
Authors: Lidia Frejo; Andres Soto-Varela; Sofía Santos-Perez; Ismael Aran; Angel Batuecas-Caletrio; Vanesa Perez-Guillen; Herminio Perez-Garrigues; Jesus Fraile; Eduardo Martin-Sanz; Maria C Tapia; Gabriel Trinidad; Ana María García-Arumi; Rocío González-Aguado; Juan M Espinosa-Sanchez; Pedro Marques; Paz Perez; Jesus Benitez; Jose A Lopez-Escamez Journal: Front Neurol Date: 2016-10-24 Impact factor: 4.003